Oxybutynin Extended-Release Tablets Recalled for Failed Dissolution Specifications
Zydus Pharmaceuticals recalls Oxybutynin Chloride Extended-Release Tablets 10 mg nationwide because the medication failed dissolution specifications. Affected lot numbers: M300652 and M300651.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II drug recall with failed dissolution specifications affecting medication efficacy. No reported illnesses or injuries documented in source material, and the hazard is a quality/manufacturing issue rather than direct contamination or safety threat.
Plain-English summary
Zydus Pharmaceuticals (USA) Inc. is recalling Oxybutynin Chloride Extended-Release Tablets USP 10 mg in bottles of 100 and 500 tablets due to failed dissolution specifications. The tablets do not dissolve as intended, which affects how the medication is absorbed in the body. This recall affects 7,248 bottles distributed nationwide in the United States.
The recalled product includes bottles of 100 tablets (NDC 68382-256-01) and 500 tablets (NDC 68382-256-05). The affected lot numbers are M300652 and M300651, with expiration dates in December 2024. The medication was manufactured by Cadila Healthcare Ltd. in Ahmedabad, India, and distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, New Jersey.
Patients and healthcare providers with affected batches should contact Zydus Pharmaceuticals (USA) Inc. for further guidance. The FDA is monitoring the recall.
The recalled product
- Product
- OXYBUTYNIN (OXYBUTYNIN)
- Brand
- OXYBUTYNIN
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug
- Hazard
- dissolution-failure
- quality-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: M300652 and M300651
- exp. Dec 2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · OXYBUTYNIN
- HighPrescription Oxybutynin Extended-Release Tablets Recalled for Dissolution Failure
FDA (Drugs) · 2023-11-15
- ModerateOxybutynin Extended-Release Tablets Recalled for Failed Dissolution Test Results
FDA (Drugs) · 2023-11-15
- ModerateZydus oxybutynin extended-release tablets recalled nationwide for failed stability testing
FDA (Drugs) · 2023-11-15
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27